Guanfacine Tablet, Extended Release
Product Images NDC 70518-3809

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 70518-3809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Guanfacine Extended-Release 2 mg tablets, packaged quantity of 30 tablets. The label indicates it is a prescription drug with NDC 70518-3809-00, manufactured by TWI Pharmaceuticals USA and repackaged by RemedyRepack Inc. Storage instructions and a warning not to crush, chew, or break the tablets are included.*
FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A pharmacokinetic curve showing guanfacine plasma concentration (ng/mL) over 24 hours. Two products are compared: Guanfacine Extended-Release Tablets 1 mg QD, represented with square markers and a solid line, and Tenex 1 mg QD, with triangle markers and a dashed line. The chart illustrates concentration trends for both formulations over time.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A pharmacokinetic graph showing fold change and 90% confidence intervals in Cmax and AUC for Guanfacine Extended-Release when coadministered with various CYP3A4/5 inhibitors and inducers, as well as oral methylphenidate and lisdexamfetamine dimesylate. The x-axis indicates change relative to reference, ranging from 0 to 5, with data points plotted accordingly.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A scatter plot illustrating the pharmacokinetic interaction of Oral Methylphenidate and Lisdexamfetamine Dimesylate on Guanfacine Extended-Release. The chart shows fold changes with 90% confidence intervals for Cmax and AUC relative to a reference, with values clustered around 1.0, indicating minimal change.*
FDA Label Image

Figure-4.jpg (Figure 4)

Figure-4.jpg (Figure 4)
A Kaplan-Meier survival curve chart showing time to treatment failure (days) on the x-axis and treatment failure rate (%) on the y-axis. Two groups are compared: one labeled Placebo with a solid line and the other labeled SPD603 with a dashed line, indicating different treatment failure rates over time.*
FDA Label Image

Molecular-structure.jpg (Molecular Structure)

Molecular-structure.jpg (Molecular Structure)
Chemical structure diagram of guanfacine hydrochloride showing its molecular composition with chlorine atoms and functional groups represented.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.